scholarly journals Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

2021 ◽  
Author(s):  
Kin Israel Notarte ◽  
Israel Guerrero-Arguero ◽  
Jacqueline Veronica Velasco ◽  
Abbygail Therese Ver ◽  
Maria Helena Santos de Oliveira ◽  
...  
Keyword(s):  
Humoral Response ◽  
Serum Levels ◽  
Related Factors ◽  
Post Vaccination ◽  
Humoral Immune ◽  
Antibody Titers ◽  
Waning Immunity ◽  
Antibody Class ◽  
Antibody Decline ◽  
Primary Cycle

Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease 2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and Moderna (mRNA-1273) in preventing breakthrough infections due to diminishing humoral immunity over time. Thus, this review characterizes the kinetics of anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) antibodies after the second dose of a primary cycle of COVID-19 mRNA vaccination. A systematic search of literature was performed and a total of 18 studies (N=15,980) were identified and reviewed. The percent difference of means of reported antibody titers were then calculated to determine the decline in humoral response after the peak levels post-vaccination. Findings revealed that the peak humoral response was reached at 21-28 days after the second dose, after which serum levels progressively diminished at 4-6 months post-vaccination. Additionally, results showed that regardless of age, sex, serostatus and presence of comorbidities, longitudinal data reporting antibody measurement exhibited a decline of both anti-receptor binding domain (RBD) IgG and anti-spike IgG, ranging from 94-95% at 90-180 days and 55-85% at 140-160 days, respectively, after the peak antibody response. This suggests that the rate of antibody decline may be independent of patient-related factors and peak antibody titers but mainly a function of time and antibody class/molecular target. Hence, this study highlights the necessity of more efficient vaccination strategies to provide booster administration in attenuating the effects of waning immunity, especially in the appearance of new variants of concerns (VoCs).

scholarly journals Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1952
Author(s):  
Andrzej Tretyn ◽  
Joanna Szczepanek ◽  
Monika Skorupa ◽  
Joanna Jarkiewicz-Tretyn ◽  
Dorota Sandomierz ◽  
...  
Keyword(s):  
Cellular Response ◽  
Humoral Response ◽  
Population Based ◽  
Igg Antibodies ◽  
Post Vaccination ◽  
Vaccination Programs ◽  
Humoral Immune ◽  
Antibody Titers ◽  
Almost All ◽  
New Generation

At the end of 2020, population-based vaccination programs with new generation mRNA-based vaccines began almost all over the world. The aim of the study was to evaluate the titer of anti-SARS-CoV-2 IgG antibodies against the S1 subunit of the virus’s spike protein as a marker of the humoral response in 477 patients and the concentration of interferon-gamma as an indicator of cellular response in 28 individuals. In our studies, we used serological enzyme-linked immunosorbent assays. IgG was measured in weeks 2 and 3 after the first dose and 1–5 weeks after the second dose of an mRNA vaccine in seropositive and seronegative individuals as well as in symptomatic and asymptomatic convalescents. High levels of antibodies were observed in 98% of our vaccinated cohort, and the presence of protective T cells was confirmed in the blood samples of all participants. The humoral immune response is diversified and is visible as early as 2–3 weeks after the first dose of the mRNA vaccine. The level of protection increased significantly after the second dose, with the increase being much greater in pre-vaccine healthy subjects and less in convalescents. In the second and third weeks after the second dose, the concentration of IgG antibodies was the highest, and in the following weeks, it decreased gradually. Regular serological measurements on eight subjects show that antibody titers are lower four months after vaccination than before the second dose.

Antibody titers decline 3-month post-vaccination with BNT612b2

2021 ◽  
Author(s):  
Julien Favresse ◽  
Jean-Louis Bayart ◽  
François Mullier ◽  
Marc Elsen ◽  
Christine Eucher ◽  
...  
Keyword(s):  
Half Life ◽  
Healthcare Professionals ◽  
Vaccine Dose ◽  
Vaccination Strategy ◽  
Humoral Response ◽  
Post Vaccination ◽  
Peak Response ◽  
Antibody Titers ◽  
Antibody Decline ◽  
Kinetics Of

Abstract Introduction: Several studies reported on the humoral response in subjects having received theBNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months postvaccinationare currently lacking and are important to drive the future vaccination strategy.Methods: The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional studydesigned to assess the antibody response in a population of healthcare professionals who had receivedtwo doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred individuals underwent a blooddrawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) werecategorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collectedafter 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptorbinding domain of the S1 subunit of the spike protein were measured in all individuals at different timepoints.Results: Using a one-compartment kinetics model, the time to maximum concentration was estimatedat 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37-107days) in seronegative participants. In seropositive participants, the time to maximum concentrationwas estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46-303 days). Theantibody response was higher in seropositive compared to seronegative participants.Conclusion: In both seropositive and seronegative subjects, a significant antibody decline wasobserved at 3 months compared to the peak response. Nevertheless, the humoral response remainedrobust in all participants.

scholarly journals Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination

2021 ◽  
Author(s):  
Andrzej Tretyn ◽  
Joanna Szczepanek ◽  
Monika Skorupa ◽  
Joanna Jarkiewicz-Tretyn ◽  
Dorota Sandomierz ◽  
...  
Keyword(s):  
Cellular Response ◽  
Humoral Response ◽  
Population Based ◽  
Igg Antibodies ◽  
Post Vaccination ◽  
Vaccination Programs ◽  
Humoral Immune ◽  
Antibody Titers ◽  
Almost All ◽  
New Generation

Abstract At the end of 2020, population-based vaccination programs with new generation mRNA-based vaccines began almost all over the world. The aim of the study was to evaluate the titer of anti-SARS-CoV-2 IgG antibodies against the S1 subunit of the virus’s spike protein as a marker of the humoral response in 477 patients and the concentration of gamma interferon as an indicator of a cellular response in 28 individuals. In our studies, we used serological enzyme-linked immunosorbent assays. IgG was measured in weeks 2 and 3 after the first dose and 1–5 weeks after the second dose of an mRNA vaccine in seropositive and seronegative individuals as well as in symptomatic and asymptomatic convalescents. High levels of antibodies were observed in 98% of our vaccinated cohort, and the presence of protective T cells was confirmed in the blood samples of all participants. The humoral immune response is diversified and is visible as early as 2–3 weeks after the first dose of the mRNA vaccine. The level of protection increased significantly after the second dose, with the increase being much greater in pre-vaccine healthy subjects and less in convalescents. In the second and third weeks after the second dose, the concentration of IgG antibodies was the highest, and in the following weeks, it decreased gradually. Regular serological measurements on eight subjects show that antibody titers are lower four months after vaccination than before the second dose.

scholarly journals Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults

Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 284
Author(s):  
Hulda R. Jonsdottir ◽  
Michel Bielecki ◽  
Denise Siegrist ◽  
Thomas W. Buehrer ◽  
Roland Züst ◽  
...  
Keyword(s):  
Young Adults ◽  
Neutralizing Antibodies ◽  
Severe Disease ◽  
Humoral Response ◽  
Neutralizing Antibody ◽  
Neutralization Assay ◽  
Asymptomatic Infection ◽  
Homogeneous Population ◽  
Humoral Immune ◽  
Antibody Titers

Neutralizing antibodies are an important part of the humoral immune response to SARS-CoV-2. It is currently unclear to what extent such antibodies are produced after non-severe disease or asymptomatic infection. We studied a cluster of SARS-CoV-2 infections among a homogeneous population of 332 predominantly male Swiss soldiers and determined the neutralizing antibody response with a serum neutralization assay using a recombinant SARS-CoV-2-GFP. All patients with non-severe COVID-19 showed a swift humoral response within two weeks after the onset of symptoms, which remained stable for the duration of the study. One month after the outbreak, titers in COVID-19 convalescents did not differ from the titers of asymptomatically infected individuals. Furthermore, symptoms of COVID-19 did not correlate with neutralizing antibody titers. Therefore, we conclude that asymptomatic infection can induce the same humoral immunity as non-severe COVID-19 in young adults.

Erythropoietin and Cyclophosphamide Combined Treatment Additively Enhances Immunoglobulin Production in Mice

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4913-4913
Author(s):  
Lilach Lifshitz ◽  
Assaf Berger ◽  
Maayan Avneon ◽  
Moshe Mittelman ◽  
Drorit Neumann
Keyword(s):  
Humoral Immunity ◽  
Combined Treatment ◽  
Humoral Response ◽  
Serum Levels ◽  
Immunosuppressive Agent ◽  
Immunoglobulin Production ◽  
Humoral Immune ◽  
C57bl Mice ◽  
High Doses ◽  
Cancer Related Anemia

Abstract Erythropoietin (EPO) is an important component in the treatment of cancer patients for improvement of cancer related anemia. EPO treatment for cancer related anemia is usually combined with chemotherapy. Cyclophosphamide (CP) is a known cytotoxic alkylating agent widely used in cancer chemotherapy. While at high doses it functions as an immunosuppressive agent, the anti-neoplastic activities of CP at low doses are attributed to enhancement of cellular and humoral immunity e.g. (Berd et al., Cancer Res; 1984). We have previously shown that EPO displays anti-neoplastic activities (Mittelman, 2001, 2004) and that EPO treatment is associated with enhancement of both the humoral and cellular immune responses (Prutchi-Sagiv 2006, Katz 2007). Here we focused on a murine model of DNP-KLH-injection, used to assess the humoral response in mice. Recently we demonstrated that administration of high doses of EPO (180U×3) to DNP-KLH-injected C57BL mice resulted in an increase in anti-DNP immunoglobulin G1 (IgG1) production. The present study was designed to examine the effect of combining low dose CP (12.5mg/kg ×2) used to achieve an anti-neoplastic activity, with a lower dose of recombinant human EPO (rHuEPO; 90U×3) on the humoral immune response of the DNP-KLH-injected mice, thus simulating the conditions of patient care. Hence, we compared anti-DNP Ig serum levels in DNP-KLH-injected C57BL mice that were treated with either EPO or CP alone, or the combination of CP and EPO (CP-EPO). CP treatment alone resulted in increased levels of serum anti-DNP IgG1 (O.D.(CP) = 0.38±0.06 vs O.D.(Non treated) = 0.18±0.064). In contrast, EPO treatment alone enhanced serum levels of IgG2 (O.D.(EPO) = 0.47±0.09 vs O.D.(Non treated) = 0.18±0.069). CP or EPO alone did not affect the total levels of anti-DNP total Ig (O.D.(EPO) = 0.37±0.07 vs O.D.(Non treated) = 0.28±0.04). Yet, the combined CP-EPO treatment resulted in increased levels of anti-DNP total Ig (O.D.(EPO+CP) = 0.48±0.05 vs O.D.(EPO or CP) = 0.37±0.04), maintaining the higher levels of IgG1 (O.D.(EPO+CP) = 0.38±0.06) and IgG2 (O.D.(EPO+CP) = 0.49±0.1). In summary, the combined CP-EPO treatment additively improved immunoglobulin production, compared to treatment with CP or EPO alone. We thus demonstrate that in context of chemotherapy treatment as usually administered in the clinic, EPO can enhance humoral immunity alongside its erythropoietic activities. Our findings emphasize the role of EPO as an immunomodulator, particularly when given as treatment in a combined therapeutic panel

scholarly journals Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1092
Author(s):  
Jean-Louis Bayart ◽  
Jonathan Douxfils ◽  
Constant Gillot ◽  
Clara David ◽  
François Mullier ◽  
...  
Keyword(s):  
Half Life ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Healthcare Professionals ◽  
Humoral Response ◽  
Clinical Effectiveness ◽  
Antibody Assay ◽  
Post Vaccination ◽  
Antibody Decline

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baseline. Samples were collected at several time points. The neutralizing antibodies (NAbs) and antibodies against the nucleocapsid and the spike protein of SARS-CoV-2 were measured. At day 180, a significant antibody decline was observed in seronegative (−55.4% with total antibody assay; −89.6% with IgG assay) and seropositive individuals (−74.8% with total antibody assay; −79.4% with IgG assay). The estimated half-life of IgG from the peak humoral response was 21 days (95% CI: 13–65) in seronegative and 53 days (95% CI: 40–79) in seropositive individuals. The estimated half-life of total antibodies was longer and ranged from 68 days (95% CI: 54–90) to 114 days (95% CI: 87–167) in seropositive and seronegative individuals, respectively. The decline of NAbs was more pronounced (−98.6%) and around 45% of the subjects tested were negative at day 180. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies.

scholarly journals Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series

2021 ◽  
Author(s):  
Elisa Danese ◽  
Martina Montagnana ◽  
Gian Luca Salvagno ◽  
Matteo Gelati ◽  
Denise Peserico ◽  
...  
Keyword(s):  
Immune Response ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Protein Concentration ◽  
Venous Blood ◽  
Case Series ◽  
Vaccine Dose ◽  
Humoral Response ◽  
Post Vaccination ◽  
Humoral Immune

Background. Since universal vaccination is a pillar against coronavirus disease 2019 (COVID-19), monitoring anti-SARS-CoV-2 neutralizing antibodies is essential for deciphering post-vaccination immune response. Methods. Three healthcare workers received 30 μg BNT162b2 mRNA Covid-19 Vaccine, followed by a second identical dose, 21 days afterwards. Venous blood was drawn at baseline and at serial intervals, up to 63 days afterwards, for assessing total immunoglobulins (Ig) anti-RBD (receptor binding domain), IgG anti-S1/S2, IgG anti-RBD, IgM anti-RBD, IgM anti-N/S1 and IgA anti-S1. Results. All subjects were SARS-CoV-2 seronegative at baseline. Total Ig anti-RBD, IgG anti-S1/S2 and IgG anti-RBD levels increased between 91-368 folds until 21 days after the first vaccine dose, then reached a plateau. The levels raised further after the second dose (by ~30-, ~8- and ~8-fold, respectively), peaking at day 35, but then slightly declining and stabilizing ~50 days after the first dose. IgA anti-S1 levels increased between 7-11 days after the first dose, slightly declined before the second dose, after which levels augmented by ~24-fold from baseline. The anti-RBD and anti-N/S1 IgM kinetics were similar to that of anti-S1 IgA, though displaying substantially weaker increases and modest peaks, only 4 to 7-fold higher than baseline. Highly significant inter-correlation was noted between total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG (all r=0.99), whilst other anti-SARS-CoV-2 antibodies displayed lower, though still significant, correlations. Serum spike protein concentration was undetectable at all time points. Conclusions. BNT162b2 mRNA vaccination generates a robust humoral immune response, especially involving IgG and IgA, magnified by the second vaccine dose.

scholarly journals Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 360
Author(s):  
Michael Jahn ◽  
Johannes Korth ◽  
Oliver Dorsch ◽  
Olympia Evdoxia Anastasiou ◽  
Burkhard Sorge-Hädicke ◽  
...  
Keyword(s):  
Humoral Response ◽  
Antibody Responses ◽  
Control Group ◽  
Immune Reactivity ◽  
Preventive Strategy ◽  
Protective Effects ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Vulnerable Patients ◽  
Antibody Titers

mRNA-based SARS-CoV-2 vaccines offer a preventive strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections that is of interest in the care of patients on hemodialysis (HDP). We measured humoral immune responses in 72 HDP after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV-2 IgG ChemiLuminescent ImmunoAssay (CLIA) two weeks after the second dose. In addition, SARS-CoV-2 IgG was determined in a control of 16 healthy healthcare workers (HCW). The control group of HCW has shown a strong antibody response with a median (MD (Q1; Q3)) antibody titer of 800.0 AU/mL (520.5; 800.0). In comparison to HCW, HDP under 60 years of age responded equally (597.0 AU/mL (410.5; 800.0), p = 0.051). However, the antibody responses of the HDP negatively correlated with age (r2 = 0.2954 p < 0.0001), leading to significantly lower antibody titers in HDP over 60 years (280.0 AU/mL (45.7; 477.0), p < 0.0001). To thoroughly understand the immunogenicity of the new mRNA-based vaccines in HDP, longitudinal data on the effectiveness and durability of antibody responses are needed. Modifications of immunization schedules should be considered in HDP with low or without antibody responsiveness after standard vaccination to boost immune reactivity and prolong protective effects in these vulnerable patients.

scholarly journals INFLUENCE OF MYCOTOXINS ON IMMUNE RESPONSES AGAINST SALMONELLA TYPHIMURIUM INFECTION OF BROILER CHICKENS

2020 ◽  
Vol 51 (6) ◽  
pp. 1716-1725
Author(s):  
Jawad & ALwan
Keyword(s):  
Immune Responses ◽  
Broiler Chickens ◽  
Serum Levels ◽  
Phagocytic Index ◽  
High Dose ◽  
Negative Group ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Sterile Normal Saline ◽  
Antibody Titers

Forty broiler chickens, One - day old were randomly divided into four equal groups:  1st group was immunized with 0.5 ml of whole sonicated salmonella antigens (WSSAgs), protein concentration 1.89 mg/ml. Two dose  two weeks intervals, S/C at 7 days old  and  the  chicks  fed   contaminated diet with  mycotoxins for 7 week,   2nd group was immunized with WSSAgs only and treated  as  1st group,  3rd group fed diet contaminated with  mycotoxins  and 4th group was fed  normal diets and served as control negative group, At 30 days, skin test, phagocytic index and serum levels of antibody titers were done, then 1st ,2nd and 3rd groups were inoculated with  high dose of  virulent S.typhimurium , (1ml containing   1  10 12  CFU/ml ), I/V, and  4th group was inoculated I/V,1ml  sterile normal saline and served as control negative group , all chicks were sacrificed at  3 weeks post infection, it was recorded that mycotoxin suppress the  cellular and  humoral immune responses , phagocytic activity ,in addition to high mortality rate were found in  chicks fed contaminated diet with  and without immunization.

scholarly journals Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1508
Author(s):  
Blanka Wolszczak-Biedrzycka ◽  
Anna Bieńkowska ◽  
Justyna Dorf
Keyword(s):  
Healthcare Workers ◽  
Venous Blood ◽  
Vaccine Dose ◽  
Post Vaccination ◽  
Vaccination Programs ◽  
Humoral Immune ◽  
History Of ◽  
Antibody Titers ◽  
Antibody Levels ◽  
The Impact

At the end of 2020, COVID-19 vaccination programs were initiated in many countries, including Poland. The first vaccine approved in Poland was the BNT162b2 mRNA preparation (Pfizer/BioNTech), and the first vaccinated group were healthcare workers. The aim of the present study was to evaluate post-vaccine antibody titers 8 months after the second vaccine dose had been administered to a group of employees of the Hospital of the Ministry of the Interior and Administration in Olsztyn (Poland). The employees were divided into two groups: persons who had COVID-19 in the fourth quarter of 2020 and were vaccinated in January–February 2021, and persons without a history of COVID-19 who were vaccinated during the same period. The analyzed material was venous blood serum collected from 100 hospital employees on 23–28 September 2021. The level of anti-SARS-CoV-2 S antibodies was measured with a Roche Cobas e411 analyzer using the electrochemiluminescence (ECLIA) method. The study demonstrated that persons with a history of SARS-CoV-2 infection had significantly higher antibody levels (taking into account gender, age, type of work performed, and severity of post-vaccination symptoms) than employees without a history of COVID-19. The study also revealed that the type of work, age, gender, and the course of SARS-CoV-2 infection can influence the humoral immune response. The presented results may prove helpful in the context of administering additional vaccine doses.

Sign in / Sign up

Export Citation Format

Share Document